ECUBLENS, Switzerland, Dec. 6 /CNW Telbec/ - Neurochem (International)
Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ:
NRMX; TSX: NRM), announces that the Company has received an acknowledgement
from the United States Food and Drug Administration (FDA) that Neurochem's
response to the July 2007 approvable letter for the New Drug Application (NDA)
for eprodisate (KIACTA(TM)) for the treatment of Amyloid A (AA) amyloidosis is
a complete, Class 2 response. The PDUFA (Prescription Drug User Fee Act) goal
date by which the FDA is expected to render a decision is April 2, 2008.
The NDA for approval of eprodisate (KIACTA(TM)) for the treatment of AA
amyloidosis was filed in February 2006. The Company submitted its response to
the second approvable letter last September and this response has been
acknowledged as complete by the FDA, allowing for the Class 2 review.
"We look forward to further productive interactions with the FDA as we
enter late-stage discussions on our marketing application," said Dr. Francesco
Bellini, Neurochem Inc.'s Chairman, President and CEO.
About eprodisate (KIACTA(TM))
Eprodisate (KIACTA(TM)) was investigated in an international, randomized,
double-blind, placebo-controlled, and parallel-designed Phase II/III clinical
trial in which 183 AA amyloidosis patients were enrolled at 27 sites around
the world (Eprodisate for AA Amyloidosis Trial, EFAAT). Patients who completed
the clinical trial were eligible for enrollment in an ongoing open-label
extension study, some of whom have now been receiving eprodisate (KIACTA(TM))
for more than six years.
In September 2006, the European Medicines Agency (EMEA) confirmed that it
had commenced a regulatory review of eprodisate (KIACTA(TM)). The Marketing
Authorization Application is being reviewed under the Agency's centralized
procedure. This means that an authorization from this Agency would apply to
all 27 European Union member states, as well as to Norway and Iceland. An oral
hearing occurred with the EMEA in November 2007 to discuss outstanding issues
raised with respect to the eprodisate (KIACTA(TM)) application and a decision
from the EMEA is expected by year-end, or shortly thereafter.
The Company also filed for marketing approval for eprodisate (KIACTA(TM))
for the treatment of AA amyloidosis in Switzerland. A decision is expected in
Eprodisate (KIACTA(TM)) has received orphan drug status in the United
States, the European Union and in Switzerland.
Neurochem Inc. sponsored the EFAAT study.
About Amyloid A (AA) Amyloidosis
A progressive and fatal condition, AA amyloidosis occurs in a proportion
of patients with chronic inflammatory disorders, chronic infections and
inherited diseases such as familial Mediterranean fever. The kidney is the
organ most frequently affected and progression to dialysis/end-stage renal
disease is the most common clinical manifestation in this disease. Currently,
there is no approved therapy to treat AA amyloidosis and about half of all
patients diagnosed with the disease die within five years of diagnosis.
About Neurochem Inc.
Neurochem Inc. is a global health company focused on the research,
development and commercialization of products to provide innovative health
solutions to patients suffering from serious diseases.
To Contact Neurochem Inc.
For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1 877 680-4500 or
visit the Web Site at www.neurochem.com.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s
control. Such risks include but are not limited to: the impact of general
economic conditions, general conditions in the pharmaceutical and/or
nutraceutical industry, changes in the regulatory environment in the
jurisdictions in which the Neurochem group does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation, that actual results may vary once the final and
quality-controlled verification of data and analyses has been completed, as
well as other risks disclosed in public filings of Neurochem Inc..
Consequently, actual future results may differ materially from the anticipated
results expressed in the forward-looking statements. The reader should not
place undue reliance, if any, on any forward-looking statements included in
this news release. These statements speak only as of the date made and
Neurochem Inc. is under no obligation and disavows any intention to update or
revise such statements as a result of any event, circumstances or otherwise.
Please see the Annual Information Form of Neurochem Inc. for further risk
factors that might affect the Neurochem group and its business.
For further information:
For further information: Lise Hébert, Ph.D., Vice President, Corporate
Communications, (450) 680-4570, email@example.com